Abbott India Q1 FY27 Results: Revenue Rs 1,813 Cr, PAT Rs 428 Cr and Key Highlights
- August 13, 2026
- Posted by: Lakshit Sharma
- Category: Market
Abbott India Q1 FY27: Revenue Rs 1,813 Cr (+4.33% YoY). PAT Rs 428 Cr (+17.13% YoY). Results August 12, 2026. CMP Rs 27,560.
Quick Answer
Abbott India reported a 17% jump in net profit to Rs 428 crore in Q1 FY27, compared with Rs 365 crore in the same quarter last year. Revenue climbed 4% to Rs 1,813 crore during the June 2026 quarter, with gross profit rising to Rs 502 crore. Investors should track the recovery trajectory and operating cost trends through the rest of FY27.
Abbott India Q1 FY27 results were declared on August 12, 2026, with the pharmaceuticals company reporting a net profit (PAT) of Rs 428 crore, up 17.13% from Rs 365 crore in Q1 FY26. The figures are on a standalone basis for the quarter ended June 30, 2026.
Abbott India’s revenue for the June 2026 quarter came in at Rs 1,813 crore, slightly above the Rs 1,738 crore reported in Q1 FY26. Gross profit for the period stood at Rs 502 crore, up from Rs 426 crore a year earlier.
Click Here – Get Free Investment Predictions
Abbott India Q1 FY27 Financial Highlights
The table below breaks down the key financial figures from the Abbott India Q1 FY27 results against Q1 FY26.
| Metric | Q1 FY27 (Jun 2026) | Q1 FY26 (Jun 2025) | YoY Change |
|---|---|---|---|
| Revenue from Operations (Rs Cr) | Rs 1,813 Cr | Rs 1,738 Cr | +4.33% |
| Gross Profit (Rs Cr) | Rs 502 Cr | Rs 426 Cr | +17.99% |
| Net Profit / (Loss) – PAT (Rs Cr) | Rs 428 Cr | Rs 365 Cr | +17.13% |
Abbott India Q1 FY27 Results Performance Analysis
Use the Univest Screener to Track Live Fundamentals of Indian Stocks
The Abbott India Q1 FY27 results show revenue growth of 4.33% year on year to Rs 1,813 crore. Gross profit improved to Rs 502 crore from Rs 426 crore in Q1 FY26.
Net profit in the June 2026 quarter stood at Rs 428 crore, up 17.13% from Rs 365 crore in Q1 FY26. Investors should verify all figures against the company’s official filings on BSE and NSE.
Key Business Factors in Abbott India Q1 FY27
1. Revenue Growth Expanded the Top Line
4.33% revenue growth year on year reflects steady business activity in the Pharmaceuticals segment. The June 2026 quarter benefited from stable customer demand across core markets.
2. Gross Profit Trend
Gross profit rose to Rs 502 crore from Rs 426 crore in Q1 FY26. Better raw material costs and pricing power supported the improvement.
3. Net Profit Rose Quarter on Quarter
Net profit came in at Rs 428 crore, up 17.13% from Rs 365 crore in Q1 FY26. The double-digit profit growth signals solid earnings quality in the current business cycle.
Dividend Details
No dividend has been announced along with the Abbott India Q1 FY27 results for the quarter ended June 2026. Investors can check future dividend updates on BSE and NSE.
Abbott India FY27 Outlook After Q1 Results
The June 2026 quarter results lay a reasonable foundation for FY27. Steady revenue and profitability suggest the business is in stable condition. Investors tracking the Abbott India Q1 FY27 results should watch for management commentary on demand trends in Pharmaceuticals, raw material cost outlook, and any capex or expansion plans that could shape FY27 earnings.
Abbott India Stock Performance
Download the Univest iOS App or Univest Android App to track Abbott India share price and upcoming results.
Abbott India shares were trading at Rs 27,560 on August 12, 2026, the day the Pharmaceuticals company announced its Q1 FY27 results. Post-results price action will depend on how the market interprets the revenue and profit trajectory. Always check the latest price on NSE and BSE before making any investment decision.
Key Risks After Abbott India Q1 FY27 Results
1. Demand Slowdown in Pharmaceuticals
A pullback in Pharmaceuticals demand could weigh on revenue growth and make it harder to sustain the profitability levels seen in Q1 FY27.
2. Input Cost and Margin Pressure
Rising raw material costs or an unfavourable sales mix could squeeze gross margins and limit net profit improvement through the rest of FY27.
3. Macro and Regulatory Headwinds
Broader factors such as interest rate movements, currency volatility, and sector-specific regulatory changes remain risks to watch for the remainder of FY27.
Conclusion
The Abbott India Q1 FY27 results show revenue of Rs 1,813 crore and a net profit (PAT) of Rs 428 crore, up 17.13% from Rs 365 crore in Q1 FY26. The performance reflects the company’s current standing in the Pharmaceuticals space. Investors should go through the detailed financial statements on BSE and NSE and seek advice from a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Abbott India Q1 FY27 Results
When were the Abbott India Q1 FY27 results announced?
Ans. The Abbott India Q1 FY27 results were announced on August 12, 2026. The standalone financials cover the quarter ended June 30, 2026, and were filed with the BSE and NSE on the same date.
What was the net profit in the Abbott India Q1 FY27 results?
Ans. Net profit (PAT) stood at Rs 428 crore in Q1 FY27, up 17.13% from Rs 365 crore in Q1 FY26.
What was the revenue in the Abbott India Q1 FY27 results?
Ans. Revenue for the June 2026 quarter grew 4.33% year on year to Rs 1,813 crore from Rs 1,738 crore in Q1 FY26.
Did Abbott India declare a dividend with Q1 FY27 results?
Ans. No dividend has been declared alongside the Abbott India Q1 FY27 results for the June 2026 quarter. Any future dividend announcements will be available on the BSE and NSE portals.
What is the FY27 outlook for Abbott India after Q1 results?
Ans. The June 2026 quarterly performance signals a positive trajectory for FY27. Key factors to watch include demand trends in the Pharmaceuticals sector, margin performance, and management guidance for the year.
Is Abbott India a good stock to buy after Q1 FY27 results?
Ans. The Q1 FY27 results of Abbott India provide insight into the company’s financial health, but investment decisions should never be based on one quarter alone. This article is for educational purposes and does not constitute investment advice. Please consult a SEBI-registered advisor before making any investment decision.